GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...

Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 ...

Novo Nordisk and Anthropic will co-develop AI solutions for defined discovery bottlenecks, focusing on biological reasoning, scientific workflows, and accelerating progression from research insights ...

CGT commercial trajectories are set years before approval — and every development decision is an access decision.

Elaine Ferguson, global president at Inizio Medical, spoke with Pharmaceutical Executive about the importance of both managing and growing talent. In today’s world, this requires people already in ...

Consolidation to a day-to-day “Novo” name seeks consistent global recognition while retaining Novo Nordisk A/S as the legal ...

Three years ago, when Pharmaceutical Executive last profiled Wendy Short Bartie, she was newly installed as senior vice ...

Cellectis has announced that its board of directors have approved a strategic transformation to become an in vivo gene ...

The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing ...

GSK agrees to acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, while Sanofi is offloading 20 mature medicines and three manufacturing sites to Cheplapharm. GSK and ...

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in ...